7,888 results match your criteria Ebola Virus


Medical populism.

Soc Sci Med 2018 Dec 7;221:1-8. Epub 2018 Dec 7.

University of Canberra, Australia. Electronic address:

Medical emergencies are staple features of today's 24/7 culture of breaking news. As politics becomes increasingly stylised, audiences fragmented, and established knowledge claims contested, health crises have become even more vulnerable to politicisation. We offer the vocabulary of medical populism to make sense of this phenomenon. Read More

View Article
December 2018
1 Read

Epidemic preparedness: why is there a need to accelerate the development of diagnostics?

Lancet Infect Dis 2018 Dec 11. Epub 2018 Dec 11.

UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address:

Global epidemics of infectious diseases are increasing in frequency and severity. Diagnostics are needed for rapid identification of the cause of the epidemic to facilitate effective control and prevention. Lessons learned from the recent Ebola virus and Zika virus epidemics are that delay in developing the right diagnostic for the right population at the right time has been a costly barrier to disease control and prevention. Read More

View Article
December 2018

Self-Replicating RNA Viruses for RNA Therapeutics.

Molecules 2018 Dec 13;23(12). Epub 2018 Dec 13.

PanTherapeutics, Route de Lavaux 49, CH1095 Lutry, Switzerland.

Self-replicating single-stranded RNA viruses such as alphaviruses, flaviviruses, measles viruses, and rhabdoviruses provide efficient delivery and high-level expression of therapeutic genes due to their high capacity of RNA replication. This has contributed to novel approaches for therapeutic applications including vaccine development and gene therapy-based immunotherapy. Numerous studies in animal tumor models have demonstrated that self-replicating RNA viral vectors can generate antibody responses against infectious agents and tumor cells. Read More

View Article
December 2018

Virus and host interactions critical for filoviral RNA synthesis as therapeutic targets.

Antiviral Res 2018 Dec 11. Epub 2018 Dec 11.

Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

Filoviruses, which include Ebola virus and Marburg virus, are negative-sense RNA viruses associated with sporadic outbreaks of severe viral hemorrhagic fever characterized by uncontrolled virus replication. The extreme virulence and emerging nature of these zoonotic pathogens make them a significant threat to human health. Replication of the filovirus genome and production of viral RNAs requires the function of a complex of four viral proteins, the nucleoprotein (NP), viral protein 35 (VP35), viral protein 30 (VP30) and large protein (L). Read More

View Article
December 2018

Protein Interaction Mapping Identifies RBBP6 as a Negative Regulator of Ebola Virus Replication.

Cell 2018 Dec;175(7):1917-1930.e13

Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA 94158, USA; J. David Gladstone Institutes, San Francisco, CA 94158, USA. Electronic address:

Ebola virus (EBOV) infection often results in fatal illness in humans, yet little is known about how EBOV usurps host pathways during infection. To address this, we used affinity tag-purification mass spectrometry (AP-MS) to generate an EBOV-host protein-protein interaction (PPI) map. We uncovered 194 high-confidence EBOV-human PPIs, including one between the viral transcription regulator VP30 and the host ubiquitin ligase RBBP6. Read More

View Article
December 2018
1 Read

Deception through Mimicry: A Cellular Antiviral Strategy.

Cell 2018 Dec;175(7):1728-1729

Department of Integrative Structural and Computational Biology, the Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address:

Viruses use mimicry to hijack cellular machinery, but can human cells use mimicry as an antiviral approach? Batra et al. identify a novel antiviral restriction factor, RBBP6, by characterizing the cellular interactome of Ebola virus. RBBP6 targets the Ebola virus transcription factor VP30 by mimicking the binding of Ebola virus nucleoprotein. Read More

View Article
December 2018
1 Read

Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS.

AIDS Rev 2018 ;20(4):187-204

Sexually Transmitted infections Unit, Centro Sanitario Sandoval. Madrid, Spain.

Nearly 1 million people become infected every day with any of the four major curable sexually transmitted infections (STIs), namely trichomoniasis, chlamydia, gonorrhea, and syphilis. Despite huge global incidence, STIs remain as neglected diseases. The success of antiretrovirals for halting progression to AIDS in HIV-infected individuals and for stopping HIV transmission to uninfected contacts, either as pre- or post-exposure -prophylaxis, has to lead to increased risky sexual behaviors through risk compensation. Read More

View Article
January 2018

Chaperoning the : Current Knowledge and Future Directions.

Viruses 2018 Dec 8;10(12). Epub 2018 Dec 8.

Institute for Integrative Systems Biology (I2SysBio), Universitat de Valencia-CSIC, 46980 Valencia, Spain.

The order harbors numerous viruses of significant relevance to human health, including both established and emerging infections. Currently, vaccines are only available for a small subset of these viruses, and antiviral therapies remain limited. Being obligate cellular parasites, viruses must utilize the cellular machinery for their replication and spread. Read More

View Article
December 2018

Equine-origin immunoglobulin fragments protects nonhuman primates from Ebola virus disease.

J Virol 2018 Dec 12. Epub 2018 Dec 12.

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Ebola virus (EBOV) infections result in aggressive hemorrhagic fever in humans with fatality rates reaching 90%, with no licensed, specific therapeutics to treat ill patients. Advances over the past 5 years have firmly established monoclonal antibody (mAb)-based products as the most promising therapeutics for treating EBOV infections, but production is costly, quantities are limited, and thus mAbs are not the best candidates for mass use in the case of an epidemic. To address this need, we generated EBOV-specific polyclonal immunoglobulin fragments F(ab') from horses hyperimmunized with an EBOV vaccine. Read More

View Article
December 2018
1 Read
4.439 Impact Factor

A point-of-care diagnostic for differentiating Ebola from endemic febrile diseases.

Sci Transl Med 2018 Dec;10(471)

Becton, Dickinson and Company, 21 Davis Drive, Research Triangle Park, NC 27709, USA.

Hemorrhagic fever outbreaks such as Ebola are difficult to detect and control because of the lack of low-cost, easily deployable diagnostics and because initial clinical symptoms mimic other endemic diseases such as malaria. Current molecular diagnostic methods such as polymerase chain reaction require trained personnel and laboratory infrastructure, hindering diagnostics at the point of need. Although rapid tests such as lateral flow can be broadly deployed, they are typically not well-suited for differentiating among multiple diseases presenting with similar symptoms. Read More

View Article
December 2018

Ebola virus, but not Marburg virus, replicates efficiently and without required adaptation in snake cells.

Virus Evol 2018 Jul 28;4(2):vey034. Epub 2018 Nov 28.

Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA.

Ebola virus (EBOV) disease is a viral hemorrhagic fever with a high case-fatality rate in humans. This disease is caused by four members of the filoviral genus , including EBOV. The natural hosts reservoirs of ebolaviruses remain to be identified. Read More

View Article

Regulating Innate and Adaptive Immunity for Controlling SIV Infection by 25-Hydroxycholesterol.

Front Immunol 2018 21;9:2686. Epub 2018 Nov 21.

School of Public Health (Shenzhen), Sun Yat-sen University, Guangdong, China.

Persistent inflammation and extensive immune activation have been associated with HIV-1/SIV pathogenesis. Previously, we reported that cholesterol-25-hydroxylase (CH25H) and its metabolite 25-hydroxycholesterol (25-HC) had a broad antiviral activity in inhibiting Zika, Ebola, and HIV-1 infection. However, the underlying immunological mechanism of CH25H and 25-HC in inhibiting viral infection remains poorly understood. Read More

View Article
November 2018
1 Read

[Neglected patients, unexpected effects. Ebola virus disease suspected case experience.]

Sante Publique 2018 July August;30(4):565-574

Introduction: In an epidemic context, the identification of suspected cases, among alert or contact cases, leads to caring for persons for whom only a minority will be confirmed cases, with a laboratory diagnosis positive for Ebola. How are suspected cases treated that are not subsequently confirmed and how do they feel about this experience ? What are the medical or social consequences ?

Methods: A qualitative study was conducted in two countries with a high Ebola risk epidemic situation in 2015-2016 (Senegal, Côte d'Ivoire). Based on interviews with suspected cases and caregivers, 12 referral itineraries were identified for 20 people. Read More

View Article
December 2018

Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.

Vaccine 2018 Dec 6. Epub 2018 Dec 6.

Canadian Center for Vaccinology, Dalhousie University, IWK Health Centre, and the Nova Scotia Health Authority, Halifax, Nova Scotia, Canada; Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.

Introduction/hypothesis: Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014-2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study. Read More

View Article
December 2018

[Ebola virus L protein harbors a new enzymatic activity involved in the internal methylation of RNAs].

Med Sci (Paris) 2018 Nov 10;34(11):919-921. Epub 2018 Dec 10.

AFMB, CNRS, Université Aix-Marseille, UMR 7257, Case 925, 163 Avenue de Luminy, 13288 Marseille cedex 09, France.

View Article
November 2018
4 Reads

A smartphone-based rapid telemonitoring system for Ebola and Marburg disease surveillance.

ACS Sens 2018 Dec 7. Epub 2018 Dec 7.

We have developed a digital and multiplexed platform for the rapid detection and telemonitoring of infections caused by Ebola and Marburg filoviruses. The system includes a flow cell assay cartridge that captures specific antibodies with microarrayed recombinant antigens from all six species of filovirus, and a smartphone fluorescent reader for high-performance interpretation of test results. Multiplexed viral proteins, which are expandable to include greater numbers of probes, were incorporated to obtain highest confidence results by cross-correlation, and custom smartphone application was developed for data analysis, interpretation and communication. Read More

View Article
December 2018

ANTIBODY-MEDIATED PROTECTIVE MECHANISMS INDUCED BY A TRIVALENT PARAINFLUENZA-VECTORED EBOLAVIRUS VACCINE.

J Virol 2018 Dec 5. Epub 2018 Dec 5.

Department of Pathology, University of Texas Medical Branch, Galveston, TX

Ebolaviruses Zaire (EBOV), Bundibugyo (BDBV) and Sudan (SUDV) cause human disease with high case fatality rates. Experimental monovalent vaccines, which all utilize the sole envelope glycoprotein (GP), do not protect against heterologous ebolaviruses. Human parainfluenza virus type 3-vectored vaccines offer benefits including needle-free administration and induction of mucosal responses in the respiratory tract. Read More

View Article
December 2018
1 Read

Clinical Trials and Administration of Zika Virus Vaccine in Pregnant Women: Lessons (that Should Have Been) Learned from Excluding Immunization with the Ebola Vaccine during Pregnancy and Lactation.

Authors:
David A Schwartz

Vaccines (Basel) 2018 Dec 4;6(4). Epub 2018 Dec 4.

Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.

As evidenced from recent epidemics, both Ebola and Zika virus infection are potentially catastrophic when occurring in pregnant women. Ebola virus causes extremely high rates of mortality in both mothers and infants; Zika virus is a TORCH infection that produces a congenital malformation syndrome and pediatric neurodevelopmental abnormalities. Production of efficacious vaccines has been a public health priority for both infections. Read More

View Article
December 2018
1 Read

Jean-Jacques Muyembe Tamfum: a life's work on Ebola.

Authors:

Bull World Health Organ 2018 Dec;96(12):804-805

Jean-Jacques Muyembe Tamfum was part of the research team that investigated the first known outbreak of Ebola virus disease in 1976. He talks to Fiona Fleck about those experiences and how he and his colleagues are using the knowledge they have built up in recent Ebola outbreaks. Read More

View Article
December 2018
1 Read

Sequencing in the time of Ebola.

Nat Rev Microbiol 2019 Jan;17(1)

Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.

View Article
January 2019

Contemporary anti-Ebola drug discovery approaches and platforms.

ACS Infect Dis 2018 Dec 5. Epub 2018 Dec 5.

The Ebola virus has a grave potential to destabilise civil society as we know it. The past few deadly Ebola outbreaks were unprecedented in size: the virus spread from the epicentres of Guinea, Sierra Leone, Nigeria and Liberia. The 2014-15 Ebola West Africa outbreak was associated with almost 30,000 suspected or confirmed cases and over 11,000 documented deaths. Read More

View Article
December 2018
3 Reads

Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77.

Sci Rep 2018 Dec 4;8(1):17628. Epub 2018 Dec 4.

State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, People's Republic of China.

MIL77, which has a higher manufacturing capacity than ZMapp, comprises MIL77-1, MIL77-2, and MIL77-3. The mechanisms by which these antibodies inhibit glycoprotein are unclear. Infection by viruses with lipid-bilayer envelopes occurs via the fusion of the viral membrane with the membrane of the target cell. Read More

View Article
December 2018
2 Reads

Persistence and Sexual Transmission of Filoviruses.

Viruses 2018 Dec 2;10(12). Epub 2018 Dec 2.

Laboratory of Emerging and Re-Emerging Viruses, Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.

There is an increasing frequency of reports regarding the persistence of the Ebola virus (EBOV) in Ebola virus disease (EVD) survivors. During the 2014⁻2016 West African EVD epidemic, sporadic transmission events resulted in the initiation of new chains of human-to-human transmission. Multiple reports strongly suggest that these re-emergences were linked to persistent EBOV infections and included sexual transmission from EVD survivors. Read More

View Article
December 2018
2 Reads

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.

Viruses 2018 Nov 30;10(12). Epub 2018 Nov 30.

Department of Microbiology and Immunology, College of Medicine, The University of Illinois at Chicago, Chicago, IL 60612, USA.

Ebola virus is the causative agent of Ebola virus disease in humans. The lethality of Ebola virus infection is about 50%, supporting the urgent need to develop anti-Ebola drugs. Glycoprotein (GP) is the only surface protein of the Ebola virus, which is functionally critical for the virus to attach and enter the host cells, and is a promising target for anti-Ebola virus drug development. Read More

View Article
November 2018
1 Read
3.279 Impact Factor

Standardized focus assay protocol for biosafety level four viruses.

J Virol Methods 2018 Dec 1;264:51-54. Epub 2018 Dec 1.

Spiez Laboratory, Federal Office for Civil Protection, Austrasse, 3700, Spiez, Switzerland. Electronic address:

Working in accordance with biosafety level four practices is highly complex and time-consuming. Therefore, the respective laboratory protocols should be as uniform as possible, simple to perform and straightforward in readout. Here we describe the successful application of a standardized 24-well plate focus assay protocol for the titration of Zaire ebolavirus (two isolates), Marburg virus (three isolates), Lassa virus (two isolates), Crimean Congo hemorrhagic fever virus (one isolate), and tick-borne encephalitis virus (two isolates). Read More

View Article
December 2018
1 Read

Ebola Virus Infection Associated with Transmission from Survivors.

Emerg Infect Dis 2019 Feb 17;25(2). Epub 2019 Feb 17.

Ebola virus (EBOV) can persist in immunologically protected body sites in survivors of Ebola virus disease, creating the potential to initiate new chains of transmission. From the outbreak in West Africa during 2014-2016, we identified 13 possible events of viral persistence-derived transmission of EBOV (VPDTe) and applied predefined criteria to classify transmission events based on the strength of evidence for VPDTe and source and route of transmission. For 8 events, a recipient case was identified; possible source cases were identified for 5 of these 8. Read More

View Article
February 2019

Returning our Ebola medals: our opposition to the hostile environment within the NHS.

Authors:
Harriet Burn

Br J Gen Pract 2018 Dec;68(677):580

Exeter GP training programme. Email:

View Article
December 2018

Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Vaccine 2018 Nov 26. Epub 2018 Nov 26.

Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), USA; Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. Electronic address:

Live viral vectors that express heterologous antigens of the target pathogen are being investigated in the development of novel vaccines against serious infectious agents like HIV and Ebola. As some live recombinant vectored vaccines may be replication-competent, a key challenge is defining the length of time for monitoring potential adverse events following immunization (AEFI) in clinical trials and epidemiologic studies. This time period must be chosen with care and based on considerations of pre-clinical and clinical trials data, biological plausibility and practical feasibility. Read More

View Article
November 2018
3.620 Impact Factor

Integrated Disease Surveillance and Response (IDSR) in Malawi: Implementation gaps and challenges for timely alert.

PLoS One 2018 29;13(11):e0200858. Epub 2018 Nov 29.

Institute of Health and Society, University of Oslo, Oslo City, Norway.

Objective: The recent 2014 Ebola Virus Disease (EVD) outbreaks rang the bell to call upon global efforts to assist resource-constrained countries to strengthen public health surveillance system for early response. Malawi adopted the Integrated Disease Surveillance and Response (IDSR) strategy to develop its national surveillance system since 2002 and revised its guideline to fulfill the International Health Regulation (IHR) requirements in 2014. This study aimed to understand the state of IDSR implementation and differences between guideline and practice for future disease surveillance system strengthening. Read More

View Article
November 2018
3.234 Impact Factor

A Pilot Trial of Online Simulation Training for Ebola Response Education.

Health Secur 2018 Nov 29. Epub 2018 Nov 29.

Lacey MenkinSmith, MD, is an Assistant Professor and Global Health Fellowship Director, Department of Emergency Medicine; Kathy Lehman-Huskamp, MD, is an Associate Professor, Medical Director, High Risk Infectious Disease Team, and Director of Emergency Management/Disaster Preparedness, Department of Pediatrics; John J. Schaefer, MD, is Professor, Department of Anesthesia and Perioperative Medicine, and Associate Dean for Statewide Clinical Effectiveness Education; Myrtede Alfred, PhD, is a postdoctoral researcher, Department of Anesthesia and Perioperative Medicine; Ken Catchpole, PhD, is Professor, SC SmartState Endowed Chair in Clinical Practice and Human Factors, Department of Anesthesia and Perioperative Medicine; Brandy Pockrus, RN, is a critical care nurse; Dulaney A. Wilson, PhD, is an Instructor, Public Health Sciences; and J. G. Reves, MD, is Distinguished University Professor, Department of Anesthesia and Perioperative Medicine; all at the Medical University of South Carolina, Charleston, SC.

This article describes a pilot trial of an internet-distributable online software package that provides course materials and built-in evaluation tools to train healthcare workers in high-risk infectious disease response. It includes (1) an online self-study component, (2) a "hands-on" simulation workshop, and (3) a data-driven performance assessment toolset to support debriefing and course reporting. This study describes a pilot trial of the software package using a course designed to provide education in Ebola response to prepare healthcare workers to safely function as a measurable, high-reliability team in an Ebola simulated environment. Read More

View Article
November 2018
1 Read

Exploratory investigation of region level risk factors of Ebola Virus Disease in West Africa.

PeerJ 2018 19;6:e5888. Epub 2018 Nov 19.

Department of Biomedical and Diagnostic Sciences, University of Tennessee-Knoxville, Knoxville, TN, United States of America.

Background: Ebola Virus Disease (EVD) is a highly infectious disease that has produced over 25,000 cases in the past 50 years. While many past outbreaks resulted in relatively few cases, the 2014 outbreak in West Africa was the most deadly occurrence of EVD to date, producing over 15,000 confirmed cases.

Objective: In this study, we investigated population level predictors of EVD risk at the regional level in Sierra Leone, Liberia, and Guinea. Read More

View Article
November 2018
1 Read

Stigma and Ebola survivorship in Liberia: Results from a longitudinal cohort study.

PLoS One 2018 28;13(11):e0206595. Epub 2018 Nov 28.

Eternal Love Winning Africa Hospital, Paynesville, Liberia.

Background: Survivors of the 2014-2016 West Africa Ebola epidemic have been reported to suffer high levels of stigmatization after return to their communities. We sought to characterize the stigma encountered by a cohort of Ebola survivors in Liberia over time.

Methods: Ebola-related stigma was assessed from June 2015 to August 2017 in 299 adolescent and adult Liberian Ebola Survivor Cohort participants at three month intervals using adapted HIV stigma scales scored from 0 to 10 according to the proportion of answers indicating stigmatization. Read More

View Article
November 2018

Pregnant Women and the Ebola Crisis.

N Engl J Med 2018 Nov 28. Epub 2018 Nov 28.

From the Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta (L.B.H, D.J.J.); and the Departments of Pediatrics and Epidemiology, University of Florida College of Medicine and College of Public Health and Health Professions, Gainesville (S.A.R.).

View Article
November 2018
2 Reads

Ramping Up the Response to Ebola.

N Engl J Med 2018 Nov 28. Epub 2018 Nov 28.

From the Center for Health Security and the Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore.

View Article
November 2018
2 Reads

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements.

Front Microbiol 2018 12;9:2724. Epub 2018 Nov 12.

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Ebolavirus (EBOV) life cycle involves interactions with numerous host factors, but it remains poorly understood, as does pathogenesis. Herein, we synthesized 65 siRNAs targeting host genes mostly connected with aspects of the negative-sense RNA virus life cycle (including viral entry, uncoating, fusion, replication, assembly, and budding). We produced EBOV transcription- and replication-competent virus-like particles (trVLPs) to mimic the EBOV life cycle. Read More

View Article
November 2018
1 Read

Structures of Ebola and Reston Virus VP35 Oligomerization Domains and Comparative Biophysical Characterization in All Ebolavirus Species.

Structure 2018 Oct 5. Epub 2018 Oct 5.

The Max-Planck Institute of Biochemistry, Department of Molecular Structural Biology, Am Klopferspitz 18, 82152 Martinsried, Germany. Electronic address:

The multifunctional virion protein 35 (VP35) of ebolaviruses is a critical determinant of virulence and pathogenesis indispensable for viral replication and host innate immune evasion. Essential for VP35 function is homo-oligomerization via a coiled-coil motif. Here we report crystal structures of VP35 oligomerization domains from the prototypic Ebola virus (EBOV) and the non-pathogenic Reston virus (RESTV), together with a comparative biophysical characterization of the domains from all known species of the Ebolavirus genus. Read More

View Article
October 2018

The Angolan Pandemic Rapid Response Team: An Assessment, Improvement, and Development Analysis of the First Self-sufficient African National Response Team Curriculum.

Disaster Med Public Health Prep 2018 Nov 27:1-5. Epub 2018 Nov 27.

2Navy Environmental and Preventive Medicine Unit 7,Rota,Spain.

Objective: The purpose of this study was to assess, through participant self-assessment, the effectiveness of a rapid response team curriculum based on the World Health Organization (WHO) Ebola Virus Disease Consolidated Preparedness Checklist, Revision 1.

Methods: A pre-and-post survey for the purpose of process improvement assessment involving 44 individuals was conducted in Angola. The survey was conducted before and after a 6-day training workshop held in Luanda, Angola, in December 2017. Read More

View Article
November 2018

[Incident-crisis-disaster. Conceptualizing unusual biological incidents].

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018 Nov 26. Epub 2018 Nov 26.

Informationsstelle des Bundes für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland.

Unusual biological threats demand adequate preparedness efforts, as demonstrated, for example, by the Ebola virus disease outbreak in West Africa in 2014/2015 and pandemic influenza in 2009/2010. In Germany, responsibilities for such efforts are located in different governmental authorities and differ from state to state. As a result, there are many different preparedness approaches using divergent core terminology. Read More

View Article
November 2018
1 Read

Comparative Transcriptomics in Ebola Makona-Infected Ferrets, Nonhuman Primates, and Humans.

J Infect Dis 2018 Nov;218(suppl_5):S486-S495

Departments of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston.

The domestic ferret is a uniformly lethal model of infection for 3 species of Ebolavirus known to be pathogenic in humans. Reagents to systematically analyze the ferret host response to infection are lacking; however, the recent publication of a draft ferret genome has opened the potential for transcriptional analysis of ferret models of disease. In this work, we present comparative analysis of longitudinally sampled blood taken from ferrets and nonhuman primates infected with lethal doses of the Makona variant of Zaire ebolavirus. Read More

View Article
November 2018
9 Reads

Budding of Ebola Virus Particles Requires the Rab11-Dependent Endocytic Recycling Pathway.

J Infect Dis 2018 Nov;218(suppl_5):S388-S396

Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

The Ebola virus-encoded major matrix protein VP40 traffics to the plasma membrane, which leads to the formation of filamentous viral particles and subsequent viral egress. However, the cellular machineries underlying this process are not fully understood. In the present study, we have assessed the role of host endocytic recycling in Ebola virus particle formation. Read More

View Article
November 2018

Emerging infectious uveitis: Chikungunya, Dengue, Zika, Ebola.

Clin Exp Ophthalmol 2018 Nov 25. Epub 2018 Nov 25.

Flinders University College of Medicine & Public Health, Adelaide, Australia.

Recently recognised forms of uveitis include intraocular inflammations that occur during or following one of several emerging infectious diseases: chikungunya fever, dengue, Zika virus disease and Ebola virus disease. Anterior, intermediate, posterior and pan- uveitis have been described in individuals infected with chikungunya virus. Persons who contract dengue or Zika viruses also may develop different types of uveitis in the course of the infection: maculopathy is a common manifestation of dengue eye disease, and Zika eye disease may cause hypertensive anterior uveitis or mimic a white dot syndrome. Read More

View Article
November 2018
2 Reads

Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes.

Sci Adv 2018 Nov 21;4(11):eaau8408. Epub 2018 Nov 21.

State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.

A trimer-of-hairpins motif has been identified in triggering virus-cell fusion within a variety of viral envelopes. Chemically manipulating such a motif represents current repertoire of viral fusion inhibitors. Here, we report that triterpenoids, a class of natural products, antagonize this trimer-of-hairpins via its constitutive heptad repeat-2 (HR2), a prevalent α-helical coil in class I viral fusion proteins. Read More

View Article
November 2018
3 Reads

Management of Diabetic Ketoacidosis with Dengue Hemorrhagic Fever.

Cureus 2018 Sep 19;10(9):e3336. Epub 2018 Sep 19.

Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, THA.

Viral hemorrhagic fever is one of the most important emerging infectious diseases. Some viral hemorrhagic fevers include dengue, hantavirus, Ebola infection, and yellow fever. Dengue virus infection results in a wide spectrum of clinical diseases, including dengue hemorrhagic fever, characterized by the transient period of plasma leakage and hemorrhagic tendency. Read More

View Article
September 2018
8 Reads

Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses.

Nanomedicine 2018 Nov 22. Epub 2018 Nov 22.

Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. Electronic address:

The recent outbreaks of Ebolavirus (EBOV) in West Africa underscore the urgent need to develop an effective EBOV vaccine. Here, we report the development of synthetic nanoparticles as a safe and highly immunogenic platform for vaccination against EBOV. We show that a large recombinant EBOV antigen (rGP) can be incorporated in a configurational manner into lipid-based nanoparticles, termed interbilayer-crosslinked multilamellar vesicles (ICMVs). Read More

View Article
November 2018
7 Reads